Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
5-year follow-up of induction and consolidation with Dara/Cy/Vel/Rev/dex in HRMM (OPTIMUM/MUKnine) shows median PFS NR vs 24.4 mos for Myeloma XI; OS NR vs 57.4 mos ; median PFS2 NR vs 43.9 mos in Myeloma XI (HR 0.26).”
Title: Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial
Authors: Martin F Kaiser, Rachel H Phillip, Sarah R Brown, Amy Holroyd, Elsa Ferris, Ruth M de Tute, Sadie Roberts, Laura Clayton, Kristian Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S Houlston, Graham Jackson, Gordon Cook, Roger G Owen, Mark T Drayson, Guy Pratt, Andrew Hall, Matthew W Jenner
You can read the full article on The Lancet Oncology.
You can find other articles featuring Robert Orlowski on OncoDaily.
